CUSIP: 86627R102
Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Stock
-
Total 13F shares
-
4,054,940
-
Share change
-
+1,364,204
-
Total reported value
-
$50,865,000
-
Price per share
-
$12.55
-
Number of holders
-
20
-
Value change
-
+$17,110,046
-
Number of buys
-
15
-
Number of sells
-
3
Quarterly Holders Quick Answers
What is CUSIP 86627R102?
CUSIP 86627R102 identifies SMMT - SUMMIT THERAPEUTICS INC COM - Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2017
-
Previous quarter:
Q2 2017
Recent filing periods for CUSIP 86627R102:
Institutional Holders of SUMMIT THERAPEUTICS INC COM - Stock (SMMT) as of Q3 2017
As of 30 Sep 2017,
SUMMIT THERAPEUTICS INC COM - Stock (SMMT) was held by
20 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,054,940 shares.
The largest 10 holders included
LANSDOWNE PARTNERS (UK) LLP, Point72 Asset Management, L.P., AXA, Granite Point Capital Management, L.P., SPHERA FUNDS MANAGEMENT LTD., First Eagle Investment Management, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, RENAISSANCE TECHNOLOGIES LLC, Polar Capital LLP, and Knoll Capital Management, LP.
This page lists
20
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.